Search Results - "Donaldson, S.H"

Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation by Rowe, S.M, Accurso, F.J, Clancy, J.P, Boyle, M.P, Dunitz, J.M, Durie, P.R, Sagel, S.D, Hornick, D.B, Konstan, M.W, Donaldson, S.H, Moss, R.B, Pilewski, J.M, Rubenstein, R, Uluer, D.B, Aitken, M.L, Dong, Q, Ordonez, C.L, Campbell, P.W, Ashlock, M.A, Ramsey, B.W

Get full text

P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators by Davies, J.C., Mall, M.A., Polineni, D., Donaldson, S.H., Fajac, I., Jain, R., Rubin, B.K., Boyd, A.C., Gill, D.R., Griesenbach, U., Hyde, S.C., McLachlan, G., Avis, M., Diefenbach, C., Sigmund, R., Seibold, W., Gupta, A., Alton, E.

Get full text

P046 Lenticlair™-ON: An extension trial examining long-term safety and efficacy outcomes associated with an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with cystic fibrosis by Davies, J.C., Mall, M.A., Polineni, D., Donaldson, S.H., Fajac, I., Jain, R., Rubin, B.K., Boyd, A.C., Gill, D.R., Griesenbach, U., Hyde, S.C., McLachlan, G., Kohlbrenner, V., Sigmund, R., Engel, A., Gupta, A., Alton, E.

Get full text

Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community by Hollin, I.L., Donaldson, S.H., Roman, C., Aliaj, E., Riva, D., Boyle, M., Borowitz, D.

“…The Cystic Fibrosis Foundation (CFF) supports research programs aimed at improving care and building a successful drug development pipeline. To ensure its…”
Get full text

Building global development strategies for cf therapeutics during a transitional cftr modulator era by Mayer-Hamblett, N., van Koningsbruggen-Rietschel, S., Nichols, D.P., VanDevanter, D.R., Davies, J.C., Lee, T., Durmowicz, A.G., Ratjen, F., Konstan, M.W., Pearson, K., Bell, S.C., Clancy, J.P., Taylor-Cousar, J.L., De Boeck, K., Donaldson, S.H., Downey, D.G., Flume, P.A., Drevinek, P., Goss, C.H., Fajac, I., Magaret, A.S., Quon, B.S., Singleton, S.M., VanDalfsen, J.M., Retsch-Bogart, G.Z.

“…•Advancement of the CF therapeutics pipeline remains an important goal.•Availability of CFTR modulators impacts future CF clinical development.•Global…”
Get full text

Extracellular purines are biomarkers of neutrophilic airway inflammation by Esther, C. R., Jr, Alexis, N. E, Clas, M. L, Lazarowski, E. R, Donaldson, S. H, Pedrosa Ribeiro, C. M, Moore, C. G, Davis, S. D, Boucher, R. C

“…Purinergic signalling regulates airway defence mechanisms, suggesting that extracellular purines could serve as airway inflammation biomarkers in cystic…”
Get full text